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Foreword: 
During the past academic year and over the past summer I had the privilege of being  
involved in working with the Italian health care system for 2 months. I regularly engaged with 
doctors, residents, patients, and Italian citizens. Through my time in Italy I have recognized 
many inspiring people from all over the country who are determined to provide the best care 
possible to the patients they serve. Gaining knowledge from my experiences being involved in 
the health care system in Italy, as well as the people who reside there, I plan to address the 
treatment of diabetes within the healthcare systems in Italy and the United States.  
As a CISLA Scholar from Connecticut College, a small liberal arts college on the east 
coast of the United States, I have been prepared through Italian classes improving my language 
skills, global perspective classes teaching that different cultures have varying was of viewing the 
world, and biology and chemistry classes to help me understand the human body function in 
relation to medicine. In preparation for this analysis I have examined data surrounding the cost 
and quality of care for the management of type 1 diabetes. The underlying constant was that 
although changes may be suggested, both Italian and United States health care systems do not 
rapidly change and is quite rare for either to dramatically change the system as a whole. 
Drawing from this data I will compare aspects of the two health systems from the two countries 
in search for improvements. As Samuel Johnson said “All travel has its advantages. If the 
passenger visits better countries, he may learn to improve his own. And if fortune carries him to 
worse, he may learn to enjoy it.” 
I’d like to give a special thank you to the CISLA program for funding the opportunity to 
work in Italy, my CISLA peers for supporting each other, my advisor Professor Marc Zimmer, as 
well as Mary Devins, Cara Masullo, Betsy Lebel, Professor Marc Forster and Professor Lanoux 
for supporting me in my studies since sophomore year.  
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I. The Italian Healthcare System 
The National Health Service of Italy, or Servizio Sanitario Nazionale (SSN) in Italian, was 
created on December 23rd, 1978 and founded on the values of social financing through general 
taxation, free of charge universal coverage, and non-discriminatory access to healthcare 
services. The SSN was solidly integrated into the nation's constitution when 85% of Parliament 
agreed to enact the SSN. This ensures that every Italian in need of healthcare receives the 
service they need.  
The stated values of the SSN are “High quality healthcare for all Italians, universality, 
equity, and solidarity, (to be) at the first ranks in the world for healthy life expectancy, life 
expectancy among the best in Europe, leader in Europe for the number of free drugs, the 
excellence in transplants, the pediatrician free for all children, front runners in high-tech 
diagnostics, decreasing hospital infections, healthcare quality and safety standards, and 
prevention, to be healthy and avoid illness.” (Ministero della Salute, 2019) 
The current healthcare system of Italy is considered a regional based national health 
service (World Health Organization, 2020), while the central government controls the distribution 
of tax revenue for publicly financed health care. The central government is also responsible for 
defining the national statutory benefits package to be offered to all residents from every region. 
For background, there are 19 regions and two autonomous provinces that have the 
responsibility to organize and deliver healthcare services through local and regional health units 
(Hospital, House, etc.) (Donatini, 2016). Regional healthcare systems can vary because of the 
region's ability to determine the macrostructure of their own healthcare systems.  
The SSN is designed to publicly finance the healthcare of all citizens and legal foreign 
residents, with coverage being automatic and universal. In 2014, public financing accounted for 
75.8% of total healthcare spending, with the total expenditure being 9.1% of the GDP. The total 
GDP being 1.787 trillion euro in 2019 according to the Federal Reserve Bank of St. Louis. This 
public healthcare system is financed through a national corporate tax, 35.6% in 2012, that is 
allocated back to regions based on the proportion to the regions contribution. The less a region 
contributes to the tax, the less money it receives back leading to financial inequalities between 
regions (Donatini, 2016). Another big financial contributor to the public healthcare system is a 
fixed proportion of national value-added tax revenue, 43.7% in 2012, collected by the central 
government and redistributed to regions who do not have resources to provide essential levels 
of care.  
Each region of Italy generates their own additional revenue creating even further 
financial gaps to fund the regional units. To help mitigate this issue there is a Standing 
Conference on Relations between the State, Regions, and Autonomous Provinces to set the 
criteria, usually population size and age demographics, to allocate funding to regions through a 
capitated budget. The SSN does not allow people to opt out and seek only private care, 
however supplementary private health insurances are available (Donatini, 2016).  
Primary care and inpatient care are free upon visitation. Italy creates positive and 
negative lists based upon medical necessity, effectiveness, human dignity, appropriateness, 
and efficiency in delivery. Positive lists identify services offered to all residents like 
pharmaceuticals, while negative lists identify services that are not offered to patients like 
cosmetic surgery.  
4 
Prescription drugs have been divided into 3 tiers according to clinical effectiveness and 
cost effectiveness. “Classe A” drugs are lifesaving drugs and treatments for chronic conditions 
and are fully covered in all cases. “Classe C” drugs contain all other drugs not covered and 
“classe H” drugs can only be delivered in a hospital setting.  
There are no charges for a general practitioner visit and hospital stays. However, there 
are copayments up to EUR36.15 for each specialist visit or prescribed procedure. To combat 
the rising public debt, the government has applied an additional EUR10 copayment for each 
prescription, as well as a EUR25 for unnecessary use of emergency services (some regions 
have not invoked this copayment). There are no other deductibles and both public and private 
sectors have contractual agreements with the SSN to not charge above the scheduled fees. 
Individuals with out-of-pocket expenses over EUR129 in a year are eligible for a tax credit equal 
to roughly one-fifth of their spending and there are no caps.  
The main out of pocket expenses are mainly for drugs not covered by the public system 
and for dental care. These kinds of drugs are mainly “classe C”. Out of pocket expenses 
accounted for 22% of the individual’s total health care spending in 2015. To ensure the fairness 
costs for the Italian citizens there are exemptions from cost-sharing that are made for people 
under age 6 and over 65 who live in a household with income below EUR36,000, which is the 
nationally defined threshold. Prisoners and people with severe disabilities are exempt from all 
cost sharing. Pregnant women and people with chronic or rare diseases are all exempt from 
cost-sharing related to treatment. Additionally, many screening services are provided free of 
charge.  
 
Table 1. Demographics and Health Risk Factors in Italy (2014). 
Total Population 
(millions) 
Percentage of People 
of Population 65 and 
older  
Percentage of Adults 
who Report being 
Daily Smokers 
Prevalence of 
Obesity (BMI > 30) 
60.8 21.4% 20% 10% 
(Donatini, 2016). 
 
Table 2. Health System Statistics in Italy (2014). 
Health Care 
Spending per 
Capita 
Out-of-Pocket 
Health Care 
Spending 
Number of 
Practicing 
Physicians per 
1,000 Population 
Hospital 
Spending per 
Discharge 
Primary care 
Physician’s use 
of Electronic 
Medical Records 
$3,207 $706 3.9 $12,150 N/A 
(Donatini, 2016). 
 
Tables 1 and 2 highlight the factors affecting the healthcare system in Italy. Table 1 
displays the statistics of people in the at-risk populations. This list is in stable condition but can 
always be lower. One highlight not to be overlooked is the aging and elderly population that 
requires more health care. Table 2 shows the amount of money individuals pay for health care, 
amount of practicing physicians, and hospital spending upon discharge. The number of 
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physicians is small but almost double per 1,000 people than in the United States. The amount of 
money the hospitals spend per discharge is also smaller than in the United States, still the 
system would benefit from less hospitalizations based on these numbers. Figure 1 below is the 
organization behind the health system in Italy. 
 
Figure 1. Organization of the Health System in Italy. The bold orange line represents 
administrative prowess and the dotted orange line represents contractual agreements between 
the health sectors. The Ministry of Health has been divided into 12 boards to have an overview 
of specific fields of health care (essential levels of care and health system ethics; human 
resources and health professionals; information systems; pharmaceuticals and medical devices; 
and health care planning) or supervise the main institutions related to the Ministry of Health 
such as the National Health Council or National Institute of Public Health.  
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II. The United States Healthcare System 
Currently, there is no national health care system in the United States, however recently 
the government has been working towards a more centralized healthcare system. The health 
coverage in the United States has changed since 2010 with the introduction of the Affordable 
Care Act (ACA), establishing a “shared responsibility” between the government, employers, and 
individuals to access affordable health care (The Commonwealth Fund, 2020). 
There were 3 main objectives at the time of introduction: (1) to reform the private 
insurance market, especially for individuals and small-group purchasers, (2) to expand Medicaid 
to the working poor with income up to 133% of the federal poverty level, and (3) to change the 
way that medical decisions are made. These objectives however have nearly no influence from 
governmental regulation, but rather rely primarily on private choices (Silvers, 2013). These 
private choices are given with the expectation that rational decision making that is shaped by 
incentives, but free of other constraints will occur. The assumption is that individuals and groups 
will make rational decisions to produce quality access to medical care at an appropriate price 
financed through fair risk sharing across a large group of people, leading to affordable care.  
Health coverage remains fragmented, with many different private and public sources of 
health coverage, and large gaps between insured rates within the United States population. 
Medicare, a federal program for adults aged 65 and older, as well as some people with 
disabilities, is administered by Medicare and Medicaid Services (CMS). The CMS works in 
partnership with state governments to administer Medicare and Children’s Health Insurance 
Program (CHIP), a conglomerate of state-federal programs for low income populations.  
United States Presidents Harry S. Truman, John F. Kennedy and Bill Clinton all made 
attempts at a government-sponsored universal health care, but these attempts never came to 
fruition. Despite past efforts failing, President Obama was able to plan and put in action the 
ACA, a government sponsored health care on March 23, 2010. Even though the ACA is 
government sponsored, there still is no form of universal coverage, although it did help to drop 
the number of uninsured from around 18% prior to the ACA to around 10% currently (Berchick 
et al. 2019). Private insurance still dominates in the healthcare market as the most prominent 
way to pay for health care costs. Private insurance is regulated at the state level for the most 
part. 
In 2018 private health insurance coverage covered 67.3% of the United States 
population, while public health insurance covered 34.4% of the population. Of all the subtypes of 
health insurance coverage, employer-based insurance remained the most popular covering 
55.1% of the population. The percentage of the population with health insurance in 2018 was 
91.5%, lower than the percentage in 2017 by about 0.6%. The percentage of private health 
insurance remained the same, while those with public coverage dropped between the two 
years. As of 2018, 8.5% of the population, or 27.5 million people did not have health insurance. 
In addition, the number of uninsured children under the age of 19 increased by 0.6% between 
the years. Medicaid coverage dropped by 0.7 percentage points, while Medicare coverage rose 
0.4 percentage points (Berchick, 2019). 
 The ACA has been in place since 2014 and has worked to increase the number of 
insured in the United States, however the situation surrounding the ACA has been changing 
since the introduction of the Trump administration. As of right now the ACA is still in effect, 
however there is uncertainty of how long it will be around as the Trump administration has 
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promised to repeal this act. This is because the new administration is focused on lowering the 
rising national debt that the more publicly integrated health system the United States had been 
working to create (Anderson, 2018).  
 Prior to the initiation of the ACA in 2014, most states had individual coverage medically 
underwritten. This means that previously, medical coverage was only available to purchase for 
patients who were healthy, if a patient was unhealthy and looking to purchase insurance they 
would have a much tougher time. This made it especially difficult for those with chronic 
illnesses. The insurance companies investigated medical histories upon application, and if they 
did not like what they saw, they would not accept you. Also, those who purchased health 
insurance prior to 2014 were required to pay the whole premium on insurance themselves.  
 In the current version of  the ACA, it requires all health plans being offered in the 
individual market and small-group marker (50 or fewer employees) to cover services in 10 
essential health benefit categories (1) ambulatory patient services, (2) emergency services, (3) 
hospitalization, (4) maternity and newborn care, (5) mental health and substance use disorder 
treatment, (6) prescriptions, (7) rehabilitative services and devices, (8) laboratory services, (9) 
preventive and wellness services and chronic disease management, and (10) pediatric services. 
The individual states determine the range of specific services and how much they cover in each 
of the ten categories through the selection of a benchmark plan. This makes it so each state's 
health  coverage varies somewhat.  
  
Table 3. Demographics and Health Risk Factors in the United States (2014) 
Total Population 
(millions) 
Percentage of People 
of Population 65 and 
older  
Percentage of Adults 
who Report being 
Daily Smokers 
Prevalence of 
Obesity (BMI > 30) 
321.19 14.5% 13% 38% 
(The Commonwealth Fund, 2020). 
 
Table 4. Health System Statistics in the United States (2014) 
Health Care 
Spending per 
Capita 
Out-of-Pocket 
Health Care 
Spending 
Number of 
Practicing 
Physicians per 
1,000 Population 
Hospital 
Spending per 
Discharge 
Primary care 
Physician’s use 
of Electronic 
Medical Records 
$9,364 $1,034 2.6 $21,603 84% 
(The Commonwealth Fund, 2020). 
 
 Tables 3 and 4 highlights the factors affecting the healthcare system in the United 
States. Table 3 displays the statistics of people in the at-risk populations. This list is growing 
each year with obesity on the rise and the population over 65 growing as well. Table 4 
encaptures the amount of money individuals pays for health care, amount of practicing 
physicians, and hospital spending. The number of primary physicians is small for the amount of 
people living in the United States and the amount of money the hospitals spend per discharge is 
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very large. The system would benefit from less hospitalizations based on these numbers. Figure 
2 below is the organization behind the health system in the United States. 
 
 
Figure 2. Organization of the United States Health Care System. The orange dotted lines 
represent one organization having a form of regulation over another organization. The orange 
solid line represents how an organization has hierarchical rule over another. The solid blue lines 
represent contracts between two organizations. 
 
III. What is Diabetes? 
After eating a meal, the human body breaks down carbohydrates from foods like bread 
into various sugar molecules, one of which is glucose, the main energy source for the body. 
Glucose is absorbed into the bloodstream, then to be absorbed by cells along with the help of a 
hormone that the body produces. This hormone is called insulin and it is what allows the body to 
take glucose from the bloodstream and move it into the cells of the body. In type 1 diabetes, the 
body no longer produces insulin, while in type 2 diabetes the body no longer uses insulin 
properly, does not make enough insulin or the body has become desensitized to insulin.  
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Type 1 diabetes is known as insulin-dependent diabetes and is typically diagnosed in 
children and young adults but can develop at any age. Insulin is produced by the pancreas and 
without insulin, glucose builds up in the bloodstream and causes complications in the body. 
Type 1 diabetes is less common than type 2 diabetes, occurring in 5-10% of people living with 
diabetes. Type 1 diabetes is caused by an autoimmune reaction that destroys the insulin-
producing beta cells in the pancreas. This will go on for a few months or even years before any 
symptoms appear. Genes can be passed on from parents to children to make them more likely 
to develop type 1 diabetes. Being exposed to triggers in the environment, like a virus, can play a 
role in the development of type 1 diabetes, while diet and lifestyle habits don’t play as much of a 
role in causing type 1 diabetes (Center for Disease Control and Prevention, 2020). Currently, 
there is no known way to prevent type 1 diabetes, but it can be managed properly following a 
healthy lifestyle and diet, regular exercise, controlling blood glucose with insulin injections, 
knowing how to recognize high or low blood glucose levels, and obtaining and storing diabetes 
supply properly.  
Type 2 diabetes used to be called adult-onset diabetes, however, this has changed as 
more and more children are being diagnosed with type 2 diabetes each year. Type 2 diabetes is 
a chronic condition in which the body either resists the effect of insulin or does not produce 
enough insulin to maintain normal blood glucose levels. The causes are known to be related to 
genetics and environmental factors. There is also no known cure like type 1, but it can be 
managed in the same ways.  
People living with diabetes must pay attention to blood glucose levels to prevent 
hypoglycemia and hyperglycemia. Normal blood sugar levels can vary for adults but are 
typically considered to be 70-130 mg/dL (Center for Disease Control and Prevention, 2020). 
Hypoglycemia is the condition of low levels of blood glucose. This can happen because of the 
intake of too much insulin, waiting too long for a meal or snack, not eating enough, or getting 
extra physical activity resulting in the body using that glucose to make ATP. This needs to be 
treated immediately as there are severe complications and can lead to a diabetic coma. 
Symptoms can include shakiness, nervousness, sweating, chills, irritability, dizziness, hunger, 
weakness, anger, or sadness. Symptoms can be different from person to person. 
Hyperglycemia is the condition of high levels of blood glucose, usually above 180-200 mg/dL. 
This can be triggered by foods, illness, medication that is not treating diabetes, or not injecting 
enough insulin. It is important to treat hyperglycemia because it can lead to complications like a 
diabetic coma, ketoacidosis, and if persistent in the long-term lead to complications with the 
body's eyes, kidney, nerves, and heart. Symptoms include frequent urination, increased thirst, 
blurred vision, fatigue, and headaches (Center for Disease Control and Prevention, 2020).  
 Prediabetes is a serious health condition of elevated blood glucose levels but is not high 
enough to be completely diagnosed as type 2 diabetes. 88 million adults living in the US, more 
than 33% of American adults, have prediabetes (Center for Disease Control and Prevention, 
2020).  
 Long term complications of diabetes are important to understand. In general, the longer 
a person has diabetes and the less controlled your blood sugar, the higher the risk of 
encountering complications. Diabetes complications can be disabling or even life-threatening. 
Diabetes dramatically increases the risk of various cardiovascular problems, including coronary 
artery disease, heart attack, stroke, and atherosclerosis. When there is excess glucose into the 
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blood, it can injure capillaries that nourish your nerves, especially in the legs and feet. Blood 
glucose levels that are out of the ordinary can cause damage to the glomeruli, which are tiny 
blood vessel clusters in the kidney, damaging the system that filters waste from your blood in 
the kidney. Additionally, eye and feet problems are more common in people who have diabetes 
(Center for Disease Control and Prevention, 2020). The international diabetes federation has 
estimated that around 8.3% of adults are living with diabetes, and in less than 20 years that 
number will most likely rise above half a billion (Himabindu, 2015). 
 
Molecular Description of Disease 
 Regulation of blood glucose levels is important because there are many complications 
that can stem from mismanagement of blood glucose levels. The three main hormones that 
control blood glucose levels are insulin, glucagon, and epinephrine. 
 Insulin is synthesized as preproinsulin and later processed to proinsulin. The proinsulin 
is converted to insulin and stored in secretory granules awaiting the signal to be released. The 
synthesis of insulin is regulated at both the transcriptional and translation level. The transcription 
is regulated by the cis-acting sequences in the 5’ flanking region and by trans-activators like 
paired box gene 6 (PAX6), the pancreatic and duodenal homeobox-1 (PDX-1), MafA, and B-
2/Neurogenic differentiation 1 (NeuroD1). The stability of preproinsulin mRNA, along with its 
untranslated regions control protein translation (Fu et al. 2014). Insulin is released by the beta 
cells in the islets of Langerhans residing in the pancreas when glucose concentrations are high, 
leading to ATP being made by the citric acid cycle. There is a fusion of secretory granules with 
the plasma membrane allowing the insulin to be released with intracellular [Ca2+] being the 
primary insulin secretory signal, with cAMP signaling dependent mechanisms being important to 
regulation of secretion as well. In addition, free fatty acids and amino acids can augment 
glucose-induced insulin secretion (Fu, 2014). The beta cells can be considered a metabolic hub 
that links nutrient metabolism and the endocrine system. Insulin travels through the bloodstream 
and to muscle, brain, or adipose tissue. Once it arrives it binds to an insulin receptor activating 
further metabolic pathways resulting in glucose flowing from the bloodstream and into cells 
through the GLUT4 protein (Röder et al. 2016). The insulin transduction pathway can be 
observed below in Figure 3.  
 
(a) (b)  
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Figure 3. (a) Glucose stimulated insulin secretion. Glucose enters the cell through the GLUT2 
transporter leading to the production of pyruvate. The pyruvate is then used to create ATP that 
binds to an ATP-sensitive channel causing the release of K+ and depolarization. Voltage 
dependent Ca2+ channel is then opened causing a rise in cAMP and the release of insulin from 
secretory granules. (b) Insulin signal transduction pathway in skeletal muscle. Insulin binds to 
the insulin receptor and then interacts with the Shc and IRS pathways through phosphorylation 
increasing mitogenesis, protein synthesis, glycogen synthesis and glucose transport. The Cbl 
and PI3-kinase cause translocation of the GLUT4 receptor to the membrane to allow glucose 
into the cell (Jameson et al. 1998). 
 
 Glucagon acts when blood glucose levels are low to inhibit the breakdown of glucose 
and activates gluconeogenesis, the creation of more glucose from pyruvate, lactate, glycerol, 
and amino acids. The glucose that is made is released into the bloodstream to increase blood 
glucose levels. Glucagon is released from the alpha cells in the islets of the pancreas. Glucagon 
primarily operates in the liver (Röder, 2016). 
 Epinephrine is released when the brain encounters flight or fight situations. Epinephrine 
tells the body to increase heart rate, cause bronchial dilation, and glucose release in a 
prolonged response. Epinephrine is released from the adrenal glands. This works to increase 
the amount of glucose in the blood, which can supply cells to then produce more ATP to meet 
the body’s increased energy requirements (Röder, 2016).  
 Type I diabetes is a complex disorder resulting in multiple genes and environmental 
factors acting to cause the autoimmune attack. In monogenic type 1 diabetes IPEX (immune, 
dysfunction, polyendocrinopathy, enteropathy, X-linked), the disease is caused by a single gene 
defect in the FOXP3 gene (Ali, 2010). The mutation leads to a lack of regulatory T lymphocytes 
that results in autoimmunity in 80% of the cases and development of diabetes as early as 2 
years of age. Additionally, in the monogenic APS-I syndrome (autoimmune polyendocrinopathy 
syndrome type 1) there is a single gene mutation of the AIRE (autoimmune regulator) gene (Ali, 
2010). This leads to abnormal expression of peripheral antigens in the thymus and abnormal 
negative selection in the thymus resulting in widespread autoimmunity. 18% of children with the 
gene defect develop diabetes.  
In most cases of diabetes, the disease is not due to  a single gene defect but rather 
caused by the influence of several risk loci. The region with the greatest risk contribution of type 
1 diabetes is the major histocompatibility complex on chromosome 6 (Ali, 2010). Another region 
that shows up in genetic studies of the disease quite a bit is the promoter region 5’ of the insulin 
gene on chromosome 11 (Ali, 2010). More recent studies show that the PTPN22 gene on 
chromosome 1 has a large contribution to the disease, the question now is how these multiple 
genes interact together to bring about observed the autoimmune response.   
Type 2 diabetes is complex resulting from environmental and genetic factors. The 
common polygenic form of type 2 diabetes, that is the late-onset form, results from an early-
onset of resistance to insulin paired with functional defects in insulin secretion by beta cells in 
pancreatic islets (Kulkarni and Kahn, 2004). The precise factors leading to the late-onset form 
are unknown. The monogenic form of diabetes, known as maturity-onset diabetes of the young 
(MODY), has been studied and is known to be caused primarily by defects affecting the 
functioning of islet beta cells. There are six forms of MODY. MODY2 is caused by mutations in 
12 
the glucokinase gene. MODY4 and MODY6 are known to be caused by mutations in genes that 
encode for the pancreatic homeodomain transcription factor PDX-1 and another transcription 
factor that is required for normal development of the pancreatic islet beta cells called NeuroD1 
and BETA2. Meanwhile, MODY1, MODY3, and MODY5 are all caused by mutations in genes 
that encode for hepatocyte nuclear family (HNF) transcription factors being HNF4[alpha], 
HNF1[alpha], and HNF[beta] respectively (Kulkarni and Kahn, 2004). Kulkarni and Kahn cite 
that there has been a genome-scale analysis of genes that are regulated by three HNF 
transcription factors in both liver and pancreatic islet tissue. This analysis showed a link 
between the common late-onset type 2 diabetes and a defect in HNF4[alpha], with this defect 
possibly being a large contributor to the disease (Kulkarni and Kahn, 2004). The question now 
to ask is what other factors are affecting the pancreatic and liver islet tissue.  
 
Insulin Delivery and Blood Glucose Monitoring Technology 
 Insulin can be delivered into the human body in a multitude of ways. Insulin syringes and 
pens are one of the most common and oldest ways of delivering insulin. Insulin syringes are 
used in combination with a vial of insulin. The syringe takes up the insulin from the vial and can 
safely and effectively deliver the insulin to the glycemic target. Insulin syringes should be used 
once an injection, unfortunately in resource limited environments individuals reuse the syringe 
which can lead to infections. When a needle is reused, it is dulled and causes more pain to the 
user upon injection. Needle thickness and length needs to be considered for every patient as 
well. The thicker the needle, the more insulin can be delivered per injection, but there is also 
more pain. Studies have shown that a shorter needle helps to prevent intramuscular injections 
(American Diabetes Association, 2018). 
Insulin pens offer the added convenience of combining the vial and syringe into a single 
device, oftentimes costing more than just a syringe. A pen can be disposable with prefilled 
cartridges or reusable with replaceable insulin cartridges. As technology has progressed, 
“smart” pens have come about. A smart pen can be programmed to calculate insulin doses and 
downloadable data reports are available.  
Insulin pumps have been available for around 40 years now. They can deliver rapid 
acting insulin throughout the day to manage blood glucose levels. Insulin pumps use tubing to 
deliver the insulin into the body. There are modest advantages of using a pump such as not 
having to inject a needle after each meal and helping to reduce severe hypoglycemia rates in 
children and adults.  
Adoption of pump therapy shows geographic variation in both Italy and the United 
States. This may be related to provider preference, but more than likely reflects socioeconomic 
status. Pump therapy is more common in individuals of higher socioeconomic status based 
upon race, ethnicity, family income, regional income, and education (American Diabetes 
Association, 2018). As seen in Table 5, the urban patients are typically seen to use the pump 
more often, while less often rural youth have a pump. This is because of lower income and 
longer distances to travel for regular checkups on the pump. Seen in Figure 4, some states may 
not even provide any coverage for diabetic care, making it much more difficult for diabetics to 
receive technology like a pump. This is very similar to how some regions receive better 
healthcare than others in Italy. Some disadvantages to pump therapy include dislodgement of 
the pump placing patients at risk for ketosis and pump site activation. Also, some people have 
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problems with having a pump attached to them based upon looks and discomfort, instead 
preferring injections.  
 
 
Figure 4. State mandated insurance coverage for diabetes in the United States (Cauchi et al. 
2016).  
 
Table 5. Demographics of diabetes treatment (Stumetz et al. 2016). 
Demographic/Clinical 
characteristics 
Total sample ( n=61) Rural 56% (n=34) Urban 44% (n=27) 
Age of participating 
youth (mean+/-SD) 
13.3 +/- 3.4 13.2 +/- 3.4 13.5 +/- 3.6 
Race (% Non-
Hispanic Whites) 
85% 74% 93% 
Education level of 
caregiver (>high 
school) 
68% 63% 74% 
Family income (% 
<50K/year) 
36% 47% 22% 
Public insurance  38% 56% 15% 
HbA1c (mean+/-SD) 8.8 +/- 1.7 9.0 +/- 1.8 8.5 +/-1.6 
Insulin regime (% 
pump) 
54% 47% 63% 
 
Diabetics need to self-monitor their blood glucose to ensure proper levels. Glucose 
meters are a common way of measuring blood glucose. Interestingly, currently marketed 
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glucose meters in Italy and the rest of Europe have to meet the current International 
Organization for Standardization, while monitors marketed in the United States must meet the 
standard under which they were improved, which is not the current standard leading to many 
people getting less than the standards require. In addition, monitoring of the accuracy of the 
meters in the United States is left to the manufacturer and not often checked by an independent 
source.  
 A newer form of blood glucose monitoring is the use of a continuous glucose monitor 
(CGM). The CGM allows patients to evaluate their blood glucose responses to blood sugar 
levels through a tablet device or even a cell phone. This can be used in combination with a 
diabetic pump to allow for insulin delivery through the click of a button on the phone. This is a 
huge step in working towards preventing hypoglycemia and hyperglycemia, as well as further 
complications stemming from such instances. This could help improve the safety of diabetics, as 
well as drive their individual and hospital costs.  
 
IV. Prevalence of Diabetes in Italy 
ISTAT has been keeping track of the prevalence of diabetes in Italy since as far back as 
1980. As of 2016, 5.3% of the population had diabetes equaling up to 3.2 million people. The 
amount of the population living with diabetes has nearly doubled from 2.9% of the population in 
1980. ISTAT has identified this increase is because the life expectancy of those living with 
diabetes has increased, early diagnosis of diabetes, and aging of the population, all signs of a 
good health system. ISTAT also reports that mortality from diabetes has decreased by 20% 
across all age groups in the last decade from 2006 to 2016.  
 According to a study published in Nutrition, Metabolism and Cardiovascular Diseases 
population-based registries of both in Europe and the United States have evidence of type 1 
diabetes increasing somewhere between 2.8%-4% per year (Bruno et al. 2016). In most cases, 
they predict that the impact type 1 diabetes has on health and direct costs of young people 
living with the disease is underestimated as most registries limit the recruitment of data by up to 
14 years (Bruno, 2016). With an increase in prevalence each year, there is an increasing 
burden on the healthcare system translating into a lower quality of care for patients that are not 
supported with devoted personnel. This is particularly important among young people as they 
often have low compliance to intensive insulin treatments and adherence to scheduled visits. It 
is important to have a correct estimate on the prevalence of the disease, as well as the direct 
costs associated with type 1 diabetes. This will help health policymakers understand, plan, and 
improve treatments for the disease. 
 The Bruno study estimates an incidence rate of 16.1/100,000 people per year in Italy for 
type 1 diabetes. Prevalence of the disease in age group 0-29 increased from 137/100,000 in 
2002 to 166.9/100,000 people in 2012.  
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Figure 5. Prevalence of type 1 diabetes by 5-year age group, period 2002-2012, Italy (Bruno, 
2016). 
 
 It can be seen from Figure 5 that the prevalence of type 1 diabetes was highest in the 
25-29 age range and lowest in the 0-4 age range. This is to be expected as there are more 
people who develop type 1 diabetes each year, increasing the total number of cases within an 
age group. Figure 3 also shows how the number of diabetes cases has increased each year in 
age groups 10-14, 15-19, 20-24, and 25-29 years of age.  
 
V. Prevalence of Diabetes in the United States 
The CDC has been able to produce The National Diabetes Statistics Report, a periodic 
publication that provides information on the prevalence and incidence of diabetes and 
prediabetes, risk factors for complications, acute and long-term complications, deaths and costs 
in an effort to prevent and control diabetes across the United States (Centers for Disease 
Control and Prevention, 2020). This current update is for the year 2020. Among the United 
States population crude estimates for 2018 diagnosed and undiagnosed cases were that 34.2 
million people of all ages, 10.5% of the United States population had diabetes. In addition, 34.1 
million adults aged 18 years or older, or 13% of United States adults had diabetes. The next 
statistic is a little shocking, about 7.3 million adults aged 18 years or older who met the 
laboratory criteria for diabetes were not aware of even having diabetes, about 2.8% of the 
United States population. This suggests that better patient monitoring, screenings, and check-
ups are necessary.  
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Figure 6. Trends in age-adjusted prevalence of diagnosed diabetes, undiagnosed diabetes and 
total diabetes among adults aged 18 years or older, United States, 1999-2016 (Centers for 
Disease Control and Prevention, 2020). 
 
 Figure 6 shows that the total from 1999-2016, the prevalence of total diabetes 
significantly increased among adults 18 years or older. Prevalence rates rose from 9.5% in 
1999-2002 to 12% in 2013-2016. It seems the prevalence in undiagnosed diabetes did not 
undergo a significant change throughout the years on the graph.  
 In addition, 210,000 children and adolescents younger than age 20 years had diagnosed 
diabetes. This is equivalent to 25 per 10,000 youths. 187,000 of the children are living with type 
1 diabetes. There are 1.4 million adults aged 20 years or older that reported having type 1 
diabetes and using insulin. Additionally, 2.9 million adults aged 20 years or older reported using 
insulin within a year of their diagnosis.  
 
Figure 7. Trends in incidence of type 1 and type 2 diabetes in youth, overall and by 
race/ethnicity, 2002-2015 (Centers for Disease Control and Prevention). 
  
Figure 7 shows that for the period 2002-2015, overall incidence of type 1 and type 2 
diabetes significantly increased for children and adolescents aged less than 20 years of age; 
from 2002-2010, Hispanic children and youth had the largest significant increase in type 1 
diabetes, while from 2011-2015 non-Hispanic Asian and Pacific Islander children and youth had 
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the largest significant increase in type 1 diabetes; additionally, from 2002-2015, overall 
incidence of type 2 diabetes significantly increased.  
Diabetes has potential to lead to complications as mentioned earlier and in 2016 a total 
of 16 million emergency department visits were reported with diabetes as the listed diagnosis. 
With the amount of money spent per patient this is very taxing to the individual and system as a 
whole. This puts strain on the hospitals around the country as these could be avoidable in many 
circumstances, e.g. when a patient has to come in for hyperglycemia. This is preventable in 
cases where the patient does not have access to insulin, and then the question becomes why 
doesn’t the patient have access to insulin? Hopefully not due to economic reasons, however this 
cannot be ruled out as 8.5% of the United States population does not have health insurance.  
 
VI. The Cost of Diabetes 
The cost of diagnosed diabetes in 2017 in the United States is $327 billion, $237 billion 
attributed to direct medical costs and $90 billion in reduced productivity (American Diabetes 
Association, 2018). Care for people with diagnosed diabetes accounts for 1 in 4 healthcare 
dollars in the United States. The average medical expenditures for people diagnosed with 
diabetes is $16,750 per year, of which around 9,600 is attributed to diabetes. Furthermore, 
people living with diabetes have at least 2.3 times higher than the medical expenditures of non-
diabetic people. Additionally, the impacts of complication lead to $37.5 billion dollars lost 
because of disease-related disability and 277,000 premature deaths attributed to diabetes 
costing the economy $19.9 billion dollars (American Diabetes Association, 2018).  
Many of the costs due to diabetes can be driven down by proper management of the 
disease. This requires a good patient-doctor relationship, in which the patient becomes 
educated on the disease and trusts the doctor in following their recommended therapies and 
treatments. This could immensely reduce the costs for both individuals and hospitals. 
Implementation of new technology like the CGM would also help patients maintain balanced 
blood glucose levels and avoid complications.  
In Italy, studies conducted by Marcellusi et al. were performed to estimate the economic 
aspects in the management of diabetes in Italy. The results they obtained came from reported 
data in the Marche region in central Italy at the national level. The total economic burden of 
diabetes in Italy came to be 8.1 billion euro per year. The 8.1 billion euro was split up 22% for 
drugs, 74% hospitalizations and 4% for visits. The authors created a scenario analysis on how 
improvement of the general monitoring parameters condition the progression of diabetic 
complications. They used  hypotheses based on expert opinions. The scenario analysis 
concluded that the implementation of good clinical practice and reduction of hospital visits by 
25% could save 1.2 million euro.  
 The individual patient's costs are much lower than that of those living in the United 
States as nearly all the necessary drugs and diabetic equipment is provided by the Italian 
Health system. However, the equipment is not always the same regionally, leading towards 
some people paying more for the more advanced equipment. The bare minimum provided to 
diabetic citizens in Italy are syringes and insulin vials, as well as a glucose meter.  
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Table 6. Direct cost of diabetes to the Italian health system in 2012 in the prevalent cohort of 
type 1 diabetes in people aged 0-29 years (Marcellusi, 2016). 
Direct cost in euro for 
person per year 
Diabetic People (n = 
2905) 
Nondiabetic people 
(n = 11,620) 
Change in % 
Total Costs 2117 (1963 - 2252)  283 (262 - 303) 648% 
Drugs 467 (437 - 497) 45 (36 -52) 938% 
Insulin 347 (331-364) 0 - 
Reagent (Glucose) 
strips (etc.) 
715 (649 - 780) 0 - 
Hospitalizations 679 (579-768) 154 (136 - 169) 327% 
Outpatient 
examinations 
256 (235-274) 84 (81 - 88) 193% 
 
Table 6 works to show the cost and burden the disease has on the healthcare system. 
Examinations, consultations, and hospitalizations represent the reimbursement that was paid by 
the LHUs to healthcare providers. Drugs were valued with the public prices reimbursed by the 
NHS. Diabetic people had costs nearly 6-fold what the non-diabetic people faced. The economic 
burden is clear and only increasing each year as more people develop the disease. 
Hospitalizations decreased the older the patients were. This is representative of good 
healthcare and patients receiving education on diabetes, as well as the proper management 
supplies. The main costs of management being insulin and reagent strips.  
 
VII. Conclusions on Diabetes and the Healthcare Systems 
 There are both pros and cons to health care systems in the United States and Italy. 
There are a multitude of differing opinions on the health care systems from people within their 
countries. For example, in a survey performed by the commonwealth fund in the US, 27% of 
respondents were in favor of eliminating all private health insurance, while 40% responded they 
did not have enough information. The rest of the citizens were content with the system that was 
in place. Furthermore, 43% of democrats favored replacing all private health insurance with a 
public plan, while only 12% of republicans and 27% of independents believed this to be 
necessary (Collins and Gunja, 2019). In a survey completed by the SSN in Italy, they deemed 
that patients’ satisfaction with reference to healthcare service was remarkably high in the North, 
while reaching dissatisfaction rates of 85% in the South for some hospitals (Ferre et al. 2014). 
 The United States is the only profit motivated healthcare system in the world. 
Coincidently, or not so much, it also has the most expensive healthcare system in the world 
(Branning and Vater, 2016). The question to answer is why these costs are skyrocketing even 
more if the care is not quality of care is not improving. No part of the healthcare system wants to 
accept the blame as politicians are blaming pharmaceutical companies, who in turn blame 
healthcare insurers or pharmacy benefit managers. It seems that no one is truly happy with the 
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way things are. Branning and Vater (2016) suggest this is because of the misaligned incentives 
shown in Table 7.  
 
Table 7. Healthcare Stakeholders’ Misaligned Incentives. 
Patient Spends as little out of pocket as possible. 
Relies on third-party payers for the majority of 
healthcare costs 
Provider Earns substantial income, enough to pay 
back student loans and justify the time and 
effort in patient care 
Health Insurer Generate more in revenue than the company 
spends on medical care for money 
Pharmacy Benefit Manager Collects service fees and earns a percentage 
of savings generated on behalf of customers 
Government Spends as little taxpayer money as possible 
while attempting to care for US’ most at risk 
populations 
Pharmaceutical manufacturer Generates enough income to earn profit after 
recouping research and development and 
marketing costs 
  
One of the biggest problems in the United States healthcare system is these misaligned 
incentives interfering with quality of car. All the stakeholders listed above in Table 7 can agree 
that the main concern is quality and cost-effective care for the patient, however there are other 
factors at play getting in the way. The degree that these factors get in the way can vary from 
stakeholder to stakeholder and cannot be applied universally. These factors and motivations are 
different for every stakeholder further driving up the cost. 
In the United States, patients are usually the victims of the misaligned incentives of the 
healthcare system, but they do bear responsibility for rising costs as well. The patients do not 
value healthcare as a service in which they are willing to invest their own money upfront. They 
do not have incentives to participate in the system early to reduce the costs. Although people 
are being pushed towards high-deductible health plans that require a large payment up front, 
this does not always work. This approach can discourage patients from seeking help when they 
need necessary care when they don’t deem it essential. A person should not feel discouraged 
from receiving healthcare due to economic reasons, for if they do not there may be even worse 
economic pains and health issues than the initial visit.  
Looking at the case studies with diabetes, this type of situation can happen when a 
person has higher than normal blood glucose levels leading to ketosis or acidosis. They may be 
inclined  not to go to the hospital even though their body is being slowly poisoned due to the 
costs of the visit, on top of the insulin they already must pay for. This can also happen in the 
circumstance of hypoglycemic emergency, or even when a person does not have enough 
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insulin and cannot afford more. Studies indicate that insulin users had 1.24 times higher risk of 
cost related medication non-adherence compared to those not on insulin (Kang et al. 2018). The 
United States government’s assumption that individuals know how to make rational decisions 
about buying health insurance plans is not well placed. There is little formal education on these 
plans and most people take the cheapest plans that ultimately may not benefit them. If the 
United States can lower the amount of hospitalizations and costs associated with discharge of 
patients, the system will benefit greatly. This can only be accomplished through good general 
practice, increasing health standards, providing better education regarding individual health and 
exercise, and more funding. In conclusion in Italy, the amount of daily exercise was greater than 
in comparison in the United States, leading to 28% less obesity and lower instances of diabetes.  
In Italy, the health care system seems to be fairer to the patients, yet in reality there are 
still many disparities within the system. Offering free drugs to manage chronic diseases is a 
huge advantage for  the at-risk populations. As seen in the case studies of diabetes, it runs in 
families and greatly affects them. For many people, if diabetes does not run in their family, they 
do not give it a second thought and can very negatively economically impact people as is the 
case with the United States. However, the regionally based system results in unfair treatment, 
especially benefitting people who live in the Northern regions. The Southern regions economy 
produces a much lower GDP in comparison to the North and the regionally based healthcare 
system reflects this. For example, in the North, diabetic citizens may receive a diabetic pump to 
treat their diabetes, while citizens in the South receive syringes and vials of insulin. Italy can 
benefit greatly from looking at their own system and identifying the issues that seemingly cause 
a huge divide in the quality of care from the North to the South. Interestingly, on average the 
south tends to spend a higher percentage of their GDP on healthcare. Further studies are 
warranted to indicate if this is due to people receiving worse equipment in the south leading to 
more hospitalizations increasing the spending or solely due to having a smaller GDP in the 
south. 
Italy and the United States have similar methods of treatment. However, diabetes is 
more economically taxing for individuals who have the disease in the United States. In both 
countries there are budget cuts  to funding of research being performed on diabetes as the 
number of cases are on the rise. Figure 6 highlights the United States government spending on 
diabetic research in the United States. Type 2 focused research increased by $240 million from 
$419 million to $659 million. Meanwhile research for type 1 and general diabetes research were 
nearly slashed in half dropping by $152 million and $122 million, respectively.  
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Figure 8. National Institute of Health’s Diabetic Research Funding in 2018 vs 2016 (Juvenile 
Diabetes Care Alliance, 2019). 
 
Italian research faces similar budget cutting problems. There is also the problem of 
doctors and drug makers being promised more funds, but due to politics and budget cuts, this 
has not happened. Some doctors are starting to feel underpaid and overworked. Drug makers 
feel there are not enough funds devoted to pricey and innovative drugs, as well as limited 
adoption of cheaper generics. Massimo Scaccabarozzi, the president of Farmindustria, Italy’s 
main drug trade group has said “The government needs to acknowledge what a pivotal role we 
play for Italy, or drug makers will move somewhere else” (Paravicin, 2016).  
 The increasing rate of diabetes across the globe is associated with huge economic and 
human costs. This is troublesome, especially in some groups that are especially high at risk for 
developing the disease, such as indigenous populations in industrialized countries. There is a 
need for improvement regarding monitoring, care, and screening for diabetes across the globe 
to reduce diabetes related morbidity and mortality. People's lives are the most important aspect 
of society as society cannot exist without those lives. It is worth noting that diabetes in 2015 
directly caused 1.6 million deaths, while in 2017 an estimated 4 million deaths were attributed to 
diabetes and its complications (Mohan, 2020).  
 There are solutions that can be implemented in the two countries today to improve 
patient satisfaction and drive down costs. Single use reagent strips to read blood glucose levels 
are not as efficient as can be, albeit it necessary. In today’s world, the CGM is an extraordinary 
device and with proper funding and studies, it potentially can eliminate the need for reagent 
strips. This in the long run has potential to help the patient and help reduce costs and waste by 
producing less and less strips, instead focusing on the technology that can improve lives. The 
CGM allows the patient to always keep track of blood glucose and prevent hyperglycemic or 
hypoglycemic attacks. This would reduce hospitalizations and prevent complications, which is 
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invaluable for the patients. Furthermore, the happier a patient is, the more likely they are to 
respond positively to proper management of a disease like diabetes. The CGM is an example of 
how funding for diabetic research is ultimately one of the only things that can help benefit 
diabetic individuals and governments a lot of money and health crises.  
 Health care systems have been around for centuries, they are not something that has 
recently been devised. There are written records and physical remains found in Deir el-Medina 
in Egypt revealing the first known governmental health care system running. This was in 1292 
B.C. As technology became more prevalent in the 19th century from inventions like the 
thermometer, stethoscope, vaccination, anesthesia and more, there has been a desire to 
expand medical knowledge. Clinical researches were encouraged to specialize because this 
specialization leads to a deeper knowledge. The healthcare systems today mirror the 200-year 
old model of factory outlined by Adam Smith with specialists playing the role of pin makers 
(Anderlini, 2018). The problem with this approach is that human bodies are not the equivalent of 
a pin or an automobile. Although humans can split a job into smaller parts, we are not able to 
split a human patient into smaller parts without losing some part of the whole view (Anderlini, 
2018).  
 Although doctor specialization leads to a deeper knowledge of organs and organ 
systems, oftentimes there are key parts a doctor who specializes in one field may miss that 
pertains to another. There can also be a lack of communication between specialists leading to 
redundant testing and a lack of knowledge on how specific therapies interact with others 
(Anderlini, 2018). Improved communication between specialists will benefit the patient and drop 
costs. 
Another issue is the barrier between scientists and clinicians, who each have specialized 
in fields that dull the ability to communicate effectively. They also lack a common value system; 
doctors deal with life and death while scientists do not. For example, pharmaceutical companies 
are starting to pull out of research into Alzheimer’s as 99% of trials for Alzheimer’s drugs have 
failed in the past 15 years. There is a need for more funding towards these kinds of research as 
they can potentially prevent disease progression and complications, making the funding more 
valuable.  
  As the number of cases of diabetes and other chronic diseases rises each year, the 
direct and indirect costs of such diseases will drive up overall healthcare spending. 
Governments have choices to make, either keep letting the problems grow or attend to the 
needs of solving the health systems crises. Problems include the increasing economic costs, 
equity of treatments, and funding while combating the rising national debts. If not, the economic 
costs and toll to human health will be immense. 
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